Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

# Investor News

**Not intended for U.S. and UK Media**

## Bayer to present data on novel pulmonary hypertension drug, Riociguat, at CHEST 2012 congress in Atlanta

First data from Phase III trials for riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) in late-breaking news presentation

**Leverkusen, October 17, 2012** – Bayer HealthCare announced today that data evaluating riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) and in pulmonary arterial hypertension (PAH) will be presented at the 2012 American College of Chest Physicians (ACCP) annual meeting in Atlanta, USA, from 20th – 25th October 2012.

“We are pleased to present top-line results of riociguat and its potential as a novel treatment option for PAH, as well as for CTEPH, a disease which has no current licensed pharmacological therapy,” said Kemal Malik, member of the Bayer HealthCare Executive Committee and Head of Global Development. “It is our aim to address the unmet needs of pulmonary hypertension by providing innovative medicines.”

**Riociguat Phase III data**

Key study data will be included in the CHEST late-breaking abstracts session on October 23, 2012 from 4.30 – 5.45 pm EDT in the convention center, room C206.
Results will be presented on the efficacy and safety of riociguat in

- patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    - Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double-blind, placebo-controlled study (CHEST-1), abstract 1462924
- patients with symptomatic pulmonary arterial hypertension (PAH)
    - Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study (PATENT-1), abstract 1462799

Study abstracts are available online from today.

**About Riociguat**

Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treating different types of pulmonary hypertension. Riociguat is the first member of a novel class of compounds, the stimulators of soluble guanylate cyclase (sGC). sGC is an enzyme found in the cardiopulmonary system. When nitric oxide (NO) binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). cGMP plays an important role in regulating vascular tone, proliferation, fibrosis, and inflammation.

Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of NO and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat is believed to have a dual mode of action: sensitizing sGC to endogenous NO and also directly stimulating sGC independent of NO. With its novel mode of action, riociguat holds promise for PAH, and other forms of PH, such as chronic thromboembolic pulmonary hypertension, where no pharmacological treatment is approved.

**About Bayer HealthCare**

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Fabian Klingen (+49-214-30-35426)

**Forward-Looking Statements**
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.